Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24923
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXia, Ying-
dc.contributor.authorYassi, Nawaf-
dc.contributor.authorRaniga, Parnesh-
dc.contributor.authorBourgeat, Pierrick-
dc.contributor.authorDesmond, Patricia-
dc.contributor.authorDoecke, James-
dc.contributor.authorAmes, David-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorFowler, Christopher-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorMartins, Ralph-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorFripp, Jurgen-
dc.contributor.authorSalvado, Olivier-
dc.date2020-09-19-
dc.date.accessioned2020-10-02T03:26:51Z-
dc.date.available2020-10-02T03:26:51Z-
dc.date.issued2020-10-27-
dc.identifier.citationJournal of Alzheimer's Disease : JAD 2020; 78(1): 321-334en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/24923-
dc.description.abstractCerebrovascular disease often coexists with Alzheimer's disease (AD). While both diseases share common risk factors, their interrelationship remains unclear. Increasing the understanding of how cerebrovascular changes interact with AD is essential to develop therapeutic strategies and refine biomarkers for early diagnosis. We investigate the prevalence and risk factors for the comorbidity of amyloid-β (Aβ) and cerebrovascular disease in the Australian Imaging, Biomarkers and Lifestyle Study of Ageing, and further examine their cross-sectional association. A total of 598 participants (422 cognitively normal, 89 with mild cognitive impairment, 87 with AD) underwent positron emission tomography and structural magnetic resonance imaging for assessment of Aβ deposition and cerebrovascular disease. Individuals were categorized based on the comorbidity status of Aβ and cerebrovascular disease (V) as Aβ-V-, Aβ-V+, Aβ+V-, or Aβ+V+. Advancing age was associated with greater likelihood of cerebrovascular disease, high Aβ load and their comorbidity. Apolipoprotein E ɛ4 carriage was only associated with Aβ positivity. Greater total and regional WMH burden were observed in participants with AD. However, no association were observed between Aβ and WMH measures after stratification by clinical classification, suggesting that the observed association between AD and cerebrovascular disease was driven by the common risk factor of age. Our observations demonstrate common comorbid condition of Aβ and cerebrovascular disease in later life. While our study did not demonstrate a convincing cross-sectional association between Aβ and WMH burden, future longitudinal studies are required to further confirm this.en
dc.language.isoeng
dc.subjectAlzheimer’s diseaseen
dc.subjectamyloiden
dc.subjectcerebrovascular diseaseen
dc.subjectwhite matter hyperintensitiesen
dc.titleComorbidity of Cerebrovascular and Alzheimer's Disease in Aging.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Alzheimer's Disease : JADen
dc.identifier.affiliationCog State Ltd, Melbourne, VIC, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australiaen
dc.identifier.affiliationPopulation Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australiaen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australiaen
dc.identifier.affiliationCSIRO Data61, Brisbane, QLD, Australiaen
dc.identifier.affiliationSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, WA, Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, VIC, Australiaen
dc.identifier.affiliationDepartment of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationDepartment of Radiology, The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationThe Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, QLD, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australiaen
dc.identifier.doi10.3233/JAD-200419en
dc.type.contentTexten
dc.identifier.pubmedid32986666
local.name.researcherMasters, Colin L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

58
checked on Nov 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.